The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

The present invention relates to novel compounds and their use as fragrance materials.

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

A process for purifying a crude composition includes a monoterpene compound selected from the group consisting of monocyclic monoterpene alcohols, monocyclic monoterpene ketones, bicyclic epoxy monoterpenes and mixtures of two or more of the aforementioned compounds, such as preferably a monocyclic monoterpene alcohol. The process comprises performing a layer crystallization with a melt of the crude composition, and the melt of the crude composition subjected to the layer crystallization includes oxygen-containing solvent in a concentration of 20 ppm to 2% by weight. The oxygen-containing solvent is selected from the group consisting of water, C1-6-alcohols, C1-6-carboxylic acids, C1-6-ketones, C1-6-aidehydes, C1-12-ethers, C1-12-esters and mixtures of two or more of the aforementioned solvents.

A process for purifying a crude composition includes a monoterpene compound selected from the group consisting of monocyclic monoterpene alcohols, monocyclic monoterpene ketones, bicyclic epoxy monoterpenes and mixtures of two or more of the aforementioned compounds, such as preferably a monocyclic monoterpene alcohol. The process comprises performing a layer crystallization with a melt of the crude composition, and the melt of the crude composition subjected to the layer crystallization includes oxygen-containing solvent in a concentration of 20 ppm to 2% by weight. The oxygen-containing solvent is selected from the group consisting of water, C1-6-alcohols, C1-6-carboxylic acids, C1-6-ketones, C1-6-aidehydes, C1-12-ethers, C1-12-esters and mixtures of two or more of the aforementioned solvents.

The present invention relates to the field of catalytic hydrogenation and, more particularly, to the use of Fe complexes with tridentate ligands, having one amino or imino coordinating group and two phosphino coordinating groups, in hydrogenation processes for the reduction of ketones or aldehydes, into the corresponding alcohol or diol, respectively.

The present invention relates to the field of catalytic hydrogenation and, more particularly, to the use of Fe complexes with tridentate ligands, having one amino or imino coordinating group and two phosphino coordinating groups, in hydrogenation processes for the reduction of ketones or aldehydes, into the corresponding alcohol or diol, respectively.

According to one aspect, a process of forming a diisocyanate compound from limonene is disclosed. The process includes performing an oxidation reaction to form a limonene-ketone from limonene having a ketone group at a first position. The process includes performing a conjugate addition reaction on the limonene-ketone to form a limonene-nitrile having a nitrile group bonded at a second position. The process also includes performing a reductive amination reaction on the limonene-nitrile to form a limonene-diamine by reducing the nitrile group to form a first amine group and converting the ketone group to a second amine group. The process further includes forming the diisocyanate compound by converting the first amine group of the limonene-diamine to a first isocyanate group and the second amine group of the limonene-diamine to a second isocyanate group.

According to one aspect, a process of forming a diisocyanate compound from limonene is disclosed. The process includes performing an oxidation reaction to form a limonene-ketone from limonene having a ketone group at a first position. The process includes performing a conjugate addition reaction on the limonene-ketone to form a limonene-nitrile having a nitrile group bonded at a second position. The process also includes performing a reductive amination reaction on the limonene-nitrile to form a limonene-diamine by reducing the nitrile group to form a first amine group and converting the ketone group to a second amine group. The process further includes forming the diisocyanate compound by converting the first amine group of the limonene-diamine to a first isocyanate group and the second amine group of the limonene-diamine to a second isocyanate group.